Last reviewed · How we verify
Dexchlorpheniramine Maleate (DEXCHLORPHENIRAMINE)
Dexchlorpheniramine Maleate (DEXCHLORPHENIRAMINE) is a small molecule drug that targets the histamine H1 receptor. Originally developed, it is now off-patent and commercially available as a generic medication. It is FDA-approved to treat various allergic conditions, including allergic conjunctivitis, rhinitis, and urticaria. The commercial status of Dexchlorpheniramine Maleate is generic, with multiple manufacturers available. Key safety considerations include potential drowsiness and other central nervous system effects.
At a glance
| Generic name | DEXCHLORPHENIRAMINE |
|---|---|
| Drug class | dexchlorpheniramine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Dermatographic urticaria
- Itching of skin
- Seasonal allergic rhinitis
- Urticaria
- Vasomotor rhinitis
Common side effects
Key clinical trials
- Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis (PHASE2)
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (PHASE3)
- Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF (PHASE3)
- Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders (PHASE3)
- Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab (PHASE3)
- Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC) (PHASE2)
- Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (PHASE1,PHASE2)
- Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexchlorpheniramine Maleate CI brief — competitive landscape report
- Dexchlorpheniramine Maleate updates RSS · CI watch RSS